Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Bristol Myers Squibb is deepening its autoimmune pipeline with a multi-year collaboration with Repertoire Immune Medicines to develop tolerizing vaccines for…
Bristol Myers Squibb is betting up to $1.8 billion on Repertoire Immune Medicines' T-cell mapping platform to develop tolerizing vaccines for three autoimmune…
Repertoire Immune Medicines announced a strategic collaboration with Eli Lilly (Jan 29, 2026; $85M upfront, up to $1.84B milestones) to develop tolerizing…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Repertoire Immune Medicines and Bristol Myers Squibb announced multi-year strategic collaboration to develop tolerizing vaccines for up to three autoimmune diseases. Repertoire receives $65M upfront and up to $1.8B in development, regulatory and commercial milestones plus tiered royalties. Leverages Repertoire's DECODE platform mapping the T-cell immune synapse.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Repertoire Immune Medicines Inc. (this deal) | 2024 | $1.9B | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2024 deals · Bristol-Myers Squibb Company deals · Immunology deals